Peptide fact checks.

The evidence does not provide reliable product-specific randomized lifespan outcomes for epitalon.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Human lifespan and healthspan outcomes attributable to epitalon.

Vyleesi is approved for acquired, generalized HSDD in certain premenopausal women after specified exclusions.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The population and limitations in the current Vyleesi label.

The label explicitly says the product is not for enhancing sexual performance and is not indicated for men or postmenopausal women.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Vyleesi's labeled indication and limitations.

The trial and approval record are product-specific and do not establish equivalence for compounded material.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Compounded or research-labeled bremelanotide products.

The label and randomized trials support this defined rare-disease outcome.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Adults with a history of phototoxic reactions from erythropoietic protoporphyria.

Its approval is for pain-free light exposure in adults with EPP, not cosmetic tanning.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The current FDA-approved indication.

Different molecules and products require their own identity, quality, safety, and outcome evidence.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Other melanocortin analogues and unapproved products.

The pivotal evidence and label support vertebral and nonvertebral fracture-risk reduction in studied high-risk populations.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Labeled osteoporosis populations at high fracture risk.

Fracture prevention and acute fracture healing are different endpoints, and trial results vary by fracture setting.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Acute fracture-healing outcomes across all fracture types.

The current label includes clinically important warnings, precautions, and population restrictions.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Approved teriparatide product use.

ACTIVE found fewer new vertebral and nonvertebral fractures versus placebo in postmenopausal women with osteoporosis.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Postmenopausal women with osteoporosis at fracture risk over 18 months.

Approved indications and trial populations define the evidence boundary.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Populations outside the current label and pivotal trial.

A prescription osteoporosis benefit-risk assessment does not establish safe enhancement in healthy people.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Healthy or athletic performance use.

Controlled trials and the Gattex label support this outcome in dependent short-bowel-syndrome populations.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Adults and labeled pediatric populations with short bowel syndrome dependent on parenteral support.

The approved indication and outcome are specific to short bowel syndrome with parenteral-support dependence.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The current Gattex indication.

The same biological activity underlies important warnings, including potential acceleration of neoplastic growth.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Approved Gattex use with required screening and monitoring.

A three-person 1996 phase 1 pilot measured increased pigmentation in two of three subjects using a defined subcutaneous dose of characterised drug. That is a real pharmacological signal and nothing more: it does not establish magnitude, durability, reproducibility at consumer doses, nasal-spray dosing, or safety.

What this answer is based on

Studies of body changes in people
This answer uses a study of how the substance enters or changes the body in people. This alone does not show a health benefit.

Applies to

Pigmentation as a measured effect in a three-person 1996 pilot study using characterised drug; not consumer products, nasal sprays, or any claim about how much tan, for how long, or at what risk.

No trial of any kind has tested sunburn, ultraviolet damage, or skin cancer as an endpoint. The published record runs the other way: melanoma and dysplastic naevus case reports, a review counting four melanomas emerging from existing moles during or shortly after melanotan use, and an approved melanocortin-1 agonist whose label calls for twice-yearly full-body skin examination because it can darken pre-existing naevi.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

All protective or preventive framing, including the comparison with sunbeds.

Scenesse is a clinician-placed controlled-release implant of afamelanotide, a different molecule that binds predominantly to the melanocortin-1 receptor, approved for photosensitivity in erythropoietic protoporphyria. Vyleesi is bremelanotide, approved for a defined sexual-desire disorder in certain premenopausal women. Melanotan II is neither molecule and has no approval, no label, no established dose, and no verified vial content.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Both versions of the confusion: melanotan marketed as equivalent to the approved Scenesse implant, and melanotan II marketed as a cheaper route to the approved bremelanotide effect.

Research-use-only wording is a marketing label, not a legal status for human use. Selling and supplying melanotan injections is illegal in the UK. Australia's regulator treats melanotan II as a prescription-only medicine that is unapproved, and issued one supplier 27 infringement notices totalling AU$101,412. That same research-chemical channel is the one whose products were found to contain roughly 43 to 88 per cent of the labelled amount plus unidentified impurities.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The legality of sale and supply, which is where enforcement in these jurisdictions is directed; it says nothing about what happens to an individual purchaser.